Anne Johnson
Financieel Directeur/CFO bij ATAI LIFE SCIENCES N.V.
Vermogen: 135 406 $ op 30-04-2024
Profiel
Ms. Anne Johnson, CPA, is a Chief Financial & Accounting Officer at ATAI Life Sciences NV.
Ms. Johnson was previously employed as a Controller by Aruvant Sciences, Inc., a Corporate Controller by Chimerix, Inc., and a Vice President-Finance by Xanodyne Pharmaceuticals, Inc. She received her undergraduate degree from The University of North Carolina at Wilmington.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ATAI LIFE SCIENCES N.V.
0.04% | 09-04-2024 | 73 590 ( 0.04% ) | 135 406 $ | 30-04-2024 |
Actieve functies van Anne Johnson
Bedrijven | Functie | Begin |
---|---|---|
ATAI LIFE SCIENCES N.V. | Financieel Directeur/CFO | 13-10-2023 |
Eerdere bekende functies van Anne Johnson
Bedrijven | Functie | Einde |
---|---|---|
CHIMERIX, INC. | Comptroller/Controller/Auditor | - |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Financieel Directeur/CFO | - |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Comptroller/Controller/Auditor | - |
Opleiding van Anne Johnson
The University of North Carolina at Wilmington | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ATAI LIFE SCIENCES N.V. | Health Technology |
CHIMERIX, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |